Clinical Trials
32 trialsNCT03178552 2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT06463665 2026-06-04
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT07226999 2026-06-04
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT07625644 2026-06-04
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
SystImmune Inc.
Phase 3 Not yet recruiting
NCT04513925 2026-06-03
SKYSCRAPER-03
Hoffmann-La Roche
Phase 3 Completed
NCT04619797 2026-06-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT05703971 2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2 Recruiting
NCT04303858 2026-06-02
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT04449874 2026-06-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT06031441 2026-06-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT07472517 2026-06-02
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT07620574 2026-06-02
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Phase 3 Not yet recruiting
NCT06096779 2026-06-01
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT06537310 2026-06-01
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Active not recruiting
NCT06646276 2026-06-01
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06712355 2026-06-01
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT07195695 2026-06-01
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Boehringer Ingelheim
Phase 3 Recruiting
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT05142696 2026-05-29
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
NCT07227597 2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06077500 2026-05-27
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06496568 2026-05-27
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche
Phase 1 Active not recruiting
NCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT04250155 2026-05-26
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT04929223 2026-05-26
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT07284121 2026-05-26
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
Recruiting
NCT04302025 2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2 Recruiting
NCT04524871 2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT07235293 2026-05-22
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Medical
Phase 2 Recruiting
NCT07280377 2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2 Active not recruiting
NCT07155174 2026-05-18
SEZanne
AbbVie
Phase 2 Recruiting